Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, England, UK.
Harvard Medical School, Boston, MA, USA.
Mol Imaging Biol. 2021 Dec;23(6):797-808. doi: 10.1007/s11307-021-01612-1. Epub 2021 May 13.
Evolving scientific evidence has begun to point towards hyperphosphorylated tau as a major neurotoxic component in the pathophysiological development of many major neurodegenerative conditions. In response to a need for accurate and reliable diagnosis and disease monitoring in clinical and trial settings, there has been great effort put into the development of tau radiotracers. While first-generation and second-generation radiotracers have provided a basis for assessing tau, concerns of inadequate specificity and selectivity have continued to motivate further study of these radiotracers and the development of novel radiopharmaceuticals. Given the prospective scientific and clinical value of a valid tau radiotracer, the molecular neuroimaging community must be aware of the most recent developments in the realm of tau radiotracer development. This brief review article will critically overview the most established tau radiotracers and, most importantly, concentrate on the progress of more recently developed tau radiotracers.
不断发展的科学证据开始指向过度磷酸化的 tau 蛋白,认为它是许多主要神经退行性疾病病理生理发展的主要神经毒性成分。为了满足临床和试验环境中准确可靠诊断和疾病监测的需求,人们投入了大量精力开发 tau 放射性示踪剂。虽然第一代和第二代放射性示踪剂为评估 tau 提供了基础,但对特异性和选择性不足的担忧一直促使人们对这些放射性示踪剂进行进一步研究,并开发新的放射性药物。鉴于有效 tau 放射性示踪剂具有潜在的科学和临床价值,分子神经影像学界必须了解 tau 放射性示踪剂开发领域的最新进展。这篇简短的综述文章将批判性地概述最成熟的 tau 放射性示踪剂,最重要的是,集中讨论最近开发的 tau 放射性示踪剂的进展。